Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
49.00
-1.73 (-3.41%)
Apr 27, 2026, 11:08 AM EDT - Market open
Moderna Employees
Moderna had 4,700 employees as of December 31, 2025. The number of employees decreased by 1,100 or -18.97% compared to the previous year.
Employees
4,700
Change (1Y)
-1,100
Growth (1Y)
-18.97%
Revenue / Employee
$413,617
Profits / Employee
-$600,426
Market Cap
19.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4,700 | -1,100 | -18.97% |
| Dec 31, 2024 | 5,800 | 200 | 3.57% |
| Dec 31, 2023 | 5,600 | 1,700 | 43.59% |
| Dec 31, 2022 | 3,900 | 1,200 | 44.44% |
| Dec 31, 2021 | 2,700 | 1,400 | 107.69% |
| Dec 31, 2020 | 1,300 | 470 | 56.63% |
| Dec 31, 2019 | 830 | 70 | 9.21% |
| Dec 31, 2018 | 760 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
| BridgeBio Pharma | 839 |
MRNA News
- 2 days ago - CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
- 5 days ago - Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
- 5 days ago - Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Accesswire
- 6 days ago - Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Accesswire
- 6 days ago - Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
- 6 days ago - Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Accesswire
- 6 days ago - Moderna to Present at Upcoming Conferences in May 2026 - Accesswire
- 9 days ago - Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting - Accesswire